Article | Published:

Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes

Nature Biotechnology volume 27, pages 5965 (2009) | Download Citation

Subjects

Abstract

Delivery of genes to the brain and spinal cord across the blood-brain barrier (BBB) has not yet been achieved. Here we show that adeno-associated virus (AAV) 9 injected intravenously bypasses the BBB and efficiently targets cells of the central nervous system (CNS). Injection of AAV9-GFP into neonatal mice through the facial vein results in extensive transduction of dorsal root ganglia and motor neurons throughout the spinal cord and widespread transduction of neurons throughout the brain, including the neocortex, hippocampus and cerebellum. In adult mice, tail vein injection of AAV9-GFP leads to robust transduction of astrocytes throughout the entire CNS, with limited neuronal transduction. This approach may enable the development of gene therapies for a range of neurodegenerative diseases, such as spinal muscular atrophy, through targeting of motor neurons, and amyotrophic lateral sclerosis, through targeting of astrocytes. It may also be useful for rapid postnatal genetic manipulations in basic neuroscience studies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev. Drug Discov. 1, 131–139 (2002).

  2. 2.

    , , , & Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839–842 (2003).

  3. 3.

    et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J. Clin. Invest. 114, 1726–1731 (2004).

  4. 4.

    et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429, 413–417 (2004).

  5. 5.

    et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 11, 429–433 (2005).

  6. 6.

    et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369, 2097–2105 (2007).

  7. 7.

    et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 7, 400–408 (2008).

  8. 8.

    et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther. 19, 463–474 (2008).

  9. 9.

    et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol. Ther. 10, 671–678 (2004).

  10. 10.

    et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23, 321–328 (2005).

  11. 11.

    et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14, 45–53 (2006).

  12. 12.

    et al. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J. Virol. 79, 214–224 (2005).

  13. 13.

    et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res. 99, e3–e9 (2006).

  14. 14.

    , , & Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol. Ther. 16, 1018–1025 (2008).

  15. 15.

    , , , & Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons. Hum. Gene Ther. 19, 61–70 (2008).

  16. 16.

    et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381–6388 (2004).

  17. 17.

    & Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol. Ther. 13, 528–537 (2006).

  18. 18.

    et al. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 80, 9831–9836 (2006).

  19. 19.

    et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 10, 2112–2118 (2003).

  20. 20.

    , , , & AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Mol. Ther. 16, 89–96 (2008).

  21. 21.

    et al. Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol. Ther. 16, 1710–1718 (2008).

  22. 22.

    et al. Targeted retrograde gene delivery for neuronal protection. Mol. Ther. 5, 50–56 (2002).

  23. 23.

    et al. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 103, 19546–19551 (2006).

  24. 24.

    , , , & Efficient retrograde neuronal transduction utilizing self-complementary AAV1. Mol. Ther. 16, 296–301 (2008).

  25. 25.

    , & Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41–53 (2006).

  26. 26.

    Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell. Mol. Neurobiol. 25, 5–23 (2005).

  27. 27.

    et al. Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Mol. Ther. 14, 54–62 (2006).

  28. 28.

    & Francis Crick's legacy for neuroscience: between the alpha and the Omega. PLoS Biol. 2, e419 (2004).

  29. 29.

    et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 11, 251–253 (2008).

  30. 30.

    et al. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol. Ther. 16, 1056–1064 (2008).

  31. 31.

    et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 102, 5820–5825 (2005).

  32. 32.

    , , , & Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 12, 618–633 (2005).

  33. 33.

    , , & Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24, 198–204 (2006).

  34. 34.

    et al. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol. Ther. 16, 1252–1260 (2008).

  35. 35.

    , & DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol. Ther. 16, 1703–1709 (2008).

  36. 36.

    et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc. Natl. Acad. Sci. USA 105, 4318–4322 (2008).

  37. 37.

    , & Genetic influence on neurogenesis in the dentate gyrus of adult mice. Proc. Natl. Acad. Sci. USA 94, 10409–10414 (1997).

Download references

Acknowledgements

This work was supported by National Institutes of Health (NIH)/National Eye Institute (NEI) R21EY018491, NIH/National Institute of Neurological Disorders and Stroke (NINDS) R21NS064328, Project A.L.S. and The Muscular Dystrophy Association. We kindly thank Jeff Rothstein (Johns Hopkins University) for the EAAT2 antibody, Terri Shaffer (Nationwide Children's Hospital) for expertise in mouse tail vein injections, Michele Basso (Ohio State University) and Megan Detloff (Ohio State University) for stereology usage and advice and Phillip Popovich (Ohio State University) and Kristina Kigerl (Ohio State University) for expertise in microglial detection.

Author information

Affiliations

  1. Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, 700 Children's Drive, Columbus, Ohio 43205, USA.

    • Kevin D Foust
    • , Emily Nurre
    • , Chrystal L Montgomery
    •  & Brian K Kaspar
  2. Department of Pediatrics, College of Medicine, The Ohio State University, 700 Children's Drive, Columbus, Ohio 43205, USA.

    • Emily Nurre
    •  & Brian K Kaspar
  3. Special Pathology Services, Charles River, Preclinical Services Nevada, 6995 Longley Lane, Reno, Nevada 89511, USA.

    • Anna Hernandez
    •  & Curtis M Chan

Authors

  1. Search for Kevin D Foust in:

  2. Search for Emily Nurre in:

  3. Search for Chrystal L Montgomery in:

  4. Search for Anna Hernandez in:

  5. Search for Curtis M Chan in:

  6. Search for Brian K Kaspar in:

Contributions

K.D.F. and B.K.K. designed and executed experiments and wrote the manuscript. E.N. contributed to animal and histological experiments. C.L.M. performed adult tail vein injections. A.H. and C.M.C. performed in situ hybridization.

Competing interests

A.H. and C.M.C. are employees who receive compensation including salary benefits from Special Pathology Services, Charles River, Preclinical Services Nevada, Reno, Nevada 89511, USA.

Corresponding author

Correspondence to Brian K Kaspar.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–8

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nbt.1515